BioCentury | Apr 9, 2021
Product Development

Macrophage therapies to watch at AACR

Macrophage cell therapies may make headlines this weekend as the first CAR macrophage data in an immunocompetent animal model read out at AACR, but the conference will also showcase a spate of other strategies...
BioCentury | Mar 10, 2021

Maverick takeout adds T cell-engagers to Takeda’s solid tumor toolkit

The addition of Maverick’s T cell-engaging bispecifics technology to Takeda’s solid tumor toolkit is the latest move by the Japanese pharma to transform its once small molecule heavy pipeline to one built on multiple modalities.  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502;...
BioCentury | Feb 26, 2021
Emerging Company Profile

Immune-Onc building broad pipeline of myeloid checkpoint inhibitors

Launched in 2016, Immune-Onc is part of a growing class of immuno-oncology companies converting myeloid cells from immune-suppressing into tumor-suppressing agents. The Palo Alto-based company was co-founded by serial entrepreneur Guo-Liang Yu, an OrbiMed Advisors...
BioCentury | Feb 13, 2021
Product Development

Howdy partner: MD Anderson’s evolving industry collaboration strategy

...corporate partners. TARGETSATR (FRP1) - Ataxia telangiectasia and Rad3 related GLS - Glutaminase HLA-A2 - Major histocompatibility complex class I A 2...
BioCentury | Feb 12, 2021
Emerging Company Profile

Quell: tweaking Tregs for persistence, potency and stability

...the new cash will get lead program QEL-001, a CAR Treg cell therapy directed against HLA-A2...
...70Funds raised: £61 million ($83.6 million)Investors: Syncona Ltd., UCL Technology FundCEO: Iain McGillPatents: None issuedTARGETSHLA-A2Major histocompatibility complex class I A 2 Stephen...
BioCentury | Jan 20, 2021
Product Development

Gritstone sending a mixed-modality COVID vaccine to Phase I

NIAID and the Gates Foundation are betting Gritstone’s antigen delivery and T cell epitope prediction technologies can yield a COVID-19 vaccine with both potent CD8+ T cell immunity and neutralizing antibody...
BioCentury | Jan 12, 2021

Sanofi joins the myeloid checkpoint movement with Biond deal

Sanofi is staking claims in next-generation checkpoints through a new deal with Israeli biotech Biond around myeloid checkpoint target ILT2.  The deal with Biond Biologics Ltd., which gives the biotech $125 million up front and...
BioCentury | Dec 5, 2020
Product Development

Bispecifics spring ahead at this year’s ASH, SITC

Bispecific antibodies are starting to diverge from CAR Ts as they venture into new targets and indications in the clinic.  First-generation T cell-engaging bispecific antibodies have mirrored the...
BioCentury | Dec 1, 2020
Product Development

Moderna moves & Immunocore breaks through: a BioCentury podcast

After its latest readout positioned the company to seek FDA authorization of its COVID-19 vaccine, Moderna has begun to look ahead to unblinding the Phase III trial of mRNA-1273 so participants who received a placebo can be...
BioCentury | Nov 23, 2020
Product Development

Immunocore charts the path for bispecifics in solid tumors with Phase III readout

With a positive Phase III readout in metastatic uveal melanoma, Immunocore has become the first company to solve one of the biggest challenges in immuno-oncology: applying T cell-engaging bispecifics to solid tumors.  The data suggest...
Items per page:
1 - 10 of 688